Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Quantum Computing Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Quantum Computing Inc trades at $8.54 (market cap $1.95B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 20.5× Quantum Computing Inc's market cap. Which is the better fit depends on your goals.
| ALNY | QUBT | |
|---|---|---|
Market Cap | $39.89B | $1.95B |
Sector | Health | Technology |
52-Week High | $491.22 | $24.62 |
52-Week Low | $278.09 | $6.31 |
Enterprise Value | $38.15B | $970.72M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Quantum Computing Inc. (QUBT) trades at $8.66, down 5.36% today, with a bearish technical outlook but strong analyst support. The company reported a net loss of $18.67 million on minimal revenue of $682,000 in 2025, reflecting high cash burn. Recent strategic acquisitions and a $10 million framework agreement with Planck Dynamics highlight growth initiatives, yet profitability remains distant amid negative margins.
QUBT offers speculative upside with a consensus price target of $24.00 (177% potential), but faces significant execution and funding risks. Investors must weigh long-term quantum technology potential against persistent losses and the need for substantial capital to survive until commercialization, making it suitable only for high-risk portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
